|
Soluble CD36 ELISA Kit, Recombinant, Antibody |
|
Soluble CD36 (sCD36) clusters with markers of insulin resistance, and high sCD36 is associated with increased type 2 diabetes risk |
CONTEXT AND OBJECTIVE: Soluble CD36 (sCD36) may be an early marker of insulin resistance and atherosclerosis. The objective of this prospective study was to evaluate sCD36 as a predictor of type 2 diabetes and to study its relationship with components of the metabolic syndrome (MetSy). DESIGN, SETTING, PARTICIPANTS, AND OUTCOME MEASURES: We conducted a case-referent study nested within a population-based health survey. Baseline variables included sCD36, body mass index, blood pressure, blood lipids, adipokines, inflammatory markers, and beta-cell function. A total of 173 initially nondiabetic cohort members who developed type 2 diabetes during 10 yr of follow-up were matched (1:2) with referents. Exploratory factor analysis was applied to hypothesize affiliation of sCD36 to the MetSy components. RESULTS: Doubling of baseline sCD36 increases the odds ratio for diabetes development by 1.24 in the general study population and by 1.45 in the female population (P < 0.025). Comparing upper sCD36 quartiles with lower, odds ratio for diabetes was 4.6 in women (P = 0.001), 3.15 in men (P = 0.011), and 2.6 in obese individuals (P < 0.025). Multivariate analysis shows that sCD36 does not predict diabetes independent of fasting plasma glucose and insulin. Factor analysis of 15 variables generates a six-factor model explaining 66-69% of total variance, where sCD36, body mass index, insulin, proinsulin, and leptin were assigned to the obesity/insulin resistance cluster. CONCLUSIONS: Upper quartile sCD36 is associated with elevated diabetes risk independent of age, gender, and obesity. Baseline sCD36 does not, however, predict diabetes independent of fasting glucose and insulin. sCD36 clusters with important markers of insulin resistance and MetSy that are key predictors of type 2 diabetes. |
Handberg A, et al. J Clin Endocrinol Metab. 2010 Apr;95(4):1939-46. Epub 2010 Feb 5. |
|
|
|
Human Soluble CD36 ELISA
Code No.: SK00196-02
Size: 96 T
Price:
Standard range: 0.487-62.5 ng/ml
Sensitivity: 100 pg/ml
Sample Type: EDTA plasma, Serum
Intra-CV: 4-6%
Inter-CV: 8-12%
Protocol: PDF |
|
Code No.: SK00196-03
Size: 96 T
Price:
Standard range: 0.22 -14 ng/ml
Sensitivity: 110 pg/ml
Sample Type: EDTA plasma, Serum
Intra-CV: 4-6%
Inter-CV: 8-12%
Protocol: PDF |
|
Code No.: 00196-01-100
Size: 96 T
Price: $360.00 USD
Protein ID :NP_001001547
Gene ID : 948
Tag; His Tag on N-terminus
Data Sheet: PDF |
|
Code No.: 00196-04-100
Size: 96 T
Price: $360.00 USD
Protein ID :Q08857
Gene ID : 12491
Tag; His Tag on N-terminus
MW: 50.1 KD
Purity: more than 95% in SDS-PAGE gel
Data Sheet: PDF |
|
Code No.: A00196-01-100
Size: 100 ug
Price: $260.00 USD
Host: rabbit
Antigen: human sCD36, rec
Ab Type: Purified IgG
Purification: Protein A
Applications: E, IHC
Working Dilution: 0.1ug/ml)
Data Sheet: PDF |
|
|
Name |
Code No. |
Size |
Price ($) |
Soluble CD36 (Human) ELISA Kit |
|
96 T |
|
Soluble CD36 (Mouse) ELISA Kit |
|
96 T |
|
CD36 (Human) , ECD Rec. |
|
100 ug |
360.00 |
CD36 (Human) , ECD Rec. Biotinylated |
00196-01-50B |
50 ug |
460.00 |
CD36 (Human) , ECD Rec. Cy3 conjugated |
00196-01-50C3 |
50 ug |
520.00 |
CD36 (Human) , ECD Rec. FITC conjugated |
00196-01-50FITC |
50 ug |
460.00 |
CD36 (Human) , ECD Rec. FAM conjugated |
00196-01-50FAM |
50 ug |
460.00 |
CD36 (Human), Rec (human cells derived) |
00196-06-10 |
10 ug |
120.00 |
Anti CD36 (Human) IgG |
A00196-01-50 |
50 ug |
220.00 |
Anti CD36 (Human) monoclonal antibody |
A00196-07-50 |
50 ug |
230.00 |
CD36 (Soluble) (Mouse) Rec. |
|
100 ug |
360.00 |
CD36 (Soluble) (Mouse) Rec., Biotinylated |
00196-04-50B |
50 ug |
490.00 |
CD36 (Soluble) (Mouse) Rec., FITC conjugated |
00196-04-50FITC |
50 ug |
420.00 |
CD36 (Soluble) (Mouse) Rec., Cy3 conjugated |
00196-04-50C3 |
50 ug |
490.00 |
CD36 (Soluble) (Mouse) Rec., FAM conjugated |
00196-04-50FAM |
50 ug |
490.00 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|